Volume 57, Issue 5, Pages (May 2000)

Slides:

Advertisements

Similar presentations

Renal disease and hypertension in non–insulin-dependent diabetes mellitus Nuhad Ismail, Bryan Becker, Piotr Strzelczyk, Eberhard Ritz Kidney International.

Advertisements

Stephen P. McDonald, Graeme R. Russ Kidney International

Volume 60, Issue 1, Pages (July 2001)

Epoetin use and Kidney Disease Outcomes Quality Initiative hemoglobin targets in patients returning to dialysis with failed renal transplants C.A. Solid,

End-stage renal disease in developing countries

Volume 83, Issue 3, Pages (March 2013)

C-reactive protein and dialysis access

Volume 55, Issue 2, Pages (February 1999)

Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients Demetrios J. Kutsogiannis, R.T.Noel.

Kidney transplantation in a low-resource setting: Nigeria experience

C-reactive protein and dialysis access

Mortality caused by sepsis in patients with end-stage renal disease compared with the general population Mark J. Sarnak, Bertrand L. Jaber Kidney International

Burden of chronic kidney disease: North Africa

Haiyan Wang, Luxia Zhang, Jicheng Lv Kidney International

Long term outcome of patients with autosomal dominant polycystic kidney diseases receiving peritoneal dialysis Sanjeev Kumar, Stanley L.-S. Fan, Martin.

Steven J. Chadban, Natalie D. Staplin Kidney International

Volume 63, Issue 2, Pages (February 2003)

Comorbidity and confounding in end-stage renal disease

Volume 63, Issue 2, Pages (February 2003)

Survival advantage in Asian American end-stage renal disease patients1

Volume 68, Issue 5, Pages (November 2005)

Volume 70, Issue 11, Pages (December 2006)

Volume 77, Issue 2, Pages (January 2010)

Stephen P. McDonald Kidney International Supplements

Acute myocardial infarction in patients with end-stage renal disease

Body size and outcomes on peritoneal dialysis in the United States

Volume 70, Issue 12, Pages (December 2006)

Volume 62, Issue 1, Pages (July 2002)

Should kidney donors be genotyped for APOL1 risk alleles?

Volume 89, Issue 5, Pages (May 2016)

Volume 83, Issue 5, Pages (May 2013)

Volume 61, Issue 2, Pages (February 2002)

Elevated risk of stroke among patients with end-stage renal disease

Volume 60, Issue 1, Pages (July 2001)

Racial disparities in access to transplantation: a tough nut to crack

Counteracting progression of renal disease: A look into the future

Lynda Anne Szczech, Ira L. Lazar Kidney International

Volume 74, Issue 5, Pages (September 2008)

Volume 58, Issue 6, Pages (December 2000)

Mortality, malnutrition, and atherosclerosis in ESRD: What is the role of interleukin-6? Peter Stenvinkel, Peter Barany, Olof Heimbürger, Roberto Pecoits-Filho,

Volume 84, Issue 4, Pages (October 2013)

Arjang Djamali, Christina Kendziorski, Peter C. Brazy, Bryan N. Becker

Volume 71, Issue 12, Pages (June 2007)

Volume 87, Issue 5, Pages (May 2015)

Peter J. Conlon, Mark A. Little, Karen Pieper, Daniel B. Mark

Volume 54, Issue 2, Pages (August 1998)

Stephen P. McDonald, Graeme R. Russ Kidney International

Long-term survival in renal transplant recipients with graft function

Racial differences in survival of patients on dialysis

Epoetin use and Kidney Disease Outcomes Quality Initiative hemoglobin targets in patients returning to dialysis with failed renal transplants C.A. Solid,

Volume 61, Issue 2, Pages (February 2002)

Acute renal failure independently predicts mortality after myeloablative allogeneic hematopoietic cell transplant Chirag R. Parikh, Peter Mcsweeney,

Does equal care give equal outcomes?

Stephen P. Mcdonald, Graeme R. Russ Kidney International

Volume 72, Issue 2, Pages (July 2007)

Preemptive kidney transplantation is associated with survival benefits among pediatric patients with end-stage renal disease Sandra Amaral, Blayne A.

Volume 64, Issue 4, Pages (October 2003)

Charles A. Herzog Kidney International

Is complement a target for therapy in renal disease?

Volume 87, Issue 3, Pages (March 2015)

Volume 55, Issue 2, Pages (February 1999)

The international realities of live donor kidney transplantation

Volume 70, Issue 10, Pages (November 2006)

Kaplan-Meier estimated kidney graft and patient survival among patients with type 2 diabetes mellitus (T2DM), age 18–59 years, body mass index < 30 kg/m2.

Familial phenotype differences in PKD11

Similar risk profiles for post-transplant renal dysfunction and long-term graft failure: UNOS/OPTN database analysis Nauman Siddiqi, Maureen A. McBride,

Volume 57, Pages S44-S48 (April 2000)

Epidemiologic data of renal diseases from a single unit in China: Analysis based on 13,519 renal biopsies Lei-Shi Li, Zhi-Hong Liu Kidney International

Volume 66, Issue 5, Pages (November 2004)

Volume 60, Issue 1, Pages (July 2001)

Presentation transcript:

Volume 57, Issue 5, Pages 2129-2135 (May 2000) Simultaneous pancreas-kidney transplantation reduces excess mortality in type 1 diabetic patients with end-stage renal disease Bryan N. Becker, Peter C. Brazy, Yolanda T. Becker, Jon S. Odorico, Thomas J. Pintar, Bradley H. Collins, John D. Pirsch, Glen E. Leverson, Dennis M. Heisey, Hans W. Sollinger Kidney International Volume 57, Issue 5, Pages 2129-2135 (May 2000) DOI: 10.1046/j.1523-1755.2000.00064.x Copyright © 2000 International Society of Nephrology Terms and Conditions

Figure 1 Kaplan-Meier estimates of simultaneous pancreas-kidney (SPK), diabetic cadaveric (DM-Cad), live-donor (DM-Live), and the primary renal disease cohort (1° renal; defined in the Methods section) transplant patient survival. *P = 0.0029 1° renal vs. all others; **P = 0.004 SPK vs. DM-Cad, DM-Live. Kidney International 2000 57, 2129-2135DOI: (10.1046/j.1523-1755.2000.00064.x) Copyright © 2000 International Society of Nephrology Terms and Conditions

Figure 2 (A) Observed/expected life span for SPK (N = 335), diabetic cadaveric (DM-Cad, N = 102), live-donor (DM-Live, N = 126), *P = 0.0021 SPK vs. DM-Cad and DM-Live. (B) Observed/expected life span for SPK patients who were on dialysis at the time of transplant (N = 206) compared with diabetic cadaveric (DM-Cad) (N = 102) and live-donor (DM-Live, N = 126) renal transplant recipients. *P = 0.01 SPK vs. DM-Cad and DM-Live. Kidney International 2000 57, 2129-2135DOI: (10.1046/j.1523-1755.2000.00064.x) Copyright © 2000 International Society of Nephrology Terms and Conditions

Figure 3 Kaplan–Meier estimates of SPK (N = 215) vs. live-donor (DM-Live, N = 111) transplant recipient patient survival in patients transplanted between 1985 and 1993 (pre-mycophenolate mofetil, *P = 0.03). Kidney International 2000 57, 2129-2135DOI: (10.1046/j.1523-1755.2000.00064.x) Copyright © 2000 International Society of Nephrology Terms and Conditions

Figure 4 Kaplan-Meier estimates of SPK (N = 335), diabetic cadaveric (DM-Cad, N = 147), and live-donor (DM-Live, N = 160) renal graft survival. *P = 0.002 SPK vs. DM-Cad and DM-Live vs. DM-Cad; P = NS SPK vs. DM-Live. Kidney International 2000 57, 2129-2135DOI: (10.1046/j.1523-1755.2000.00064.x) Copyright © 2000 International Society of Nephrology Terms and Conditions